BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib

被引：2

作者：

Benjamin, Esther Sathya Bama ^{[1
]}

Ravindra, Niveditha ^{[1
]}

Rajamani, Bharathi Murugan ^{[1
]}

Anandan, Senthamizhselvi ^{[1
]}

Kausalya, Bagavathi ^{[2
]}

Veldore, Vidya ^{[2
]}

Mathews, Vikram ^{[1
]}

Velayudhan, Shaji Ramachandran

Balasubramanian, Poonkuzhali ^{[1
]}

机构：

[1] Christian Med Coll & Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India

[2] MedGenome Labs Ltd, Bengaluru, India

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 06期

关键词：

RESISTANCE;

D O I：

10.1080/10428194.2021.1872074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1528 / 1531

页数：4

共 14 条

[1] Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia [J].

Baer, Constance ;

Kern, Wolfgang ;

Koch, Sarah ;

Nadarajah, Niroshan ;

Schindela, Sonja ;

Meggendorfer, Manja ;

Haferlach, Claudia ;

Haferlach, Torsten .

HAEMATOLOGICA, 2016, 101 (07) :830-838

[2] Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? [J].

Branford, Susan ;

Melo, Junia V. ;

Hughes, Timothy P. .

BLOOD, 2009, 114 (27) :5426-5435

[3] Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment [J].

Chu, S ;

Xu, H ;

Shah, NP ;

Snyder, DS ;

Forman, SJ ;

Sawyers, CL ;

Bhatia, R .

BLOOD, 2005, 105 (05) :2093-2098

[4]

Erbilgin Y, 2018, LEUKEMIA LYMPHOMA

[5]

European LeukemiaNet, 2020, REC TREAT CHRON MYEL

[6] Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study [J].

Kizilors, Aytug ;

Crisa, Elena ;

Lea, Nicholas ;

Passera, Roberto ;

Mian, Syed ;

Anwar, Jamal ;

Best, Steve ;

Nicolini, Franck E. ;

Ireland, Robin ;

Aldouri, Maadh ;

Pocock, Christopher ;

Corbett, Tim ;

Gale, Richard ;

Bart-Smith, Emily ;

Weston-Smith, Simon ;

Wykes, Clare ;

Kulasekararaj, Austin ;

Jackson, Sophie ;

Harrington, Patrick ;

McLornan, Donal ;

Raj, Kavita ;

Pagliuca, Antonio ;

Mufti, Ghulam J. ;

de Lavallade, Hugues .

LANCET HAEMATOLOGY, 2019, 6 (05) :E276-E284

[7] Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions [J].

Markose, Preetha ;

Chendamarai, Ezhilarasi ;

Balasubramanian, Poonkuzhali ;

Velayudhan, Shaji Ramachandran ;

Srivastava, Vivi M. ;

Mathews, Vikram ;

George, Biju ;

Viswabandya, Auro ;

Srivastava, Alok ;

Chandy, Mammen .

LEUKEMIA & LYMPHOMA, 2009, 50 (12) :2092-2095

[8] BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance [J].

Parker, W. T. ;

Yeoman, A. L. ;

Jamison, B. A. ;

Yeung, D. T. ;

Scott, H. S. ;

Hughes, T. P. ;

Branford, S. .

BRITISH JOURNAL OF CANCER, 2013, 109 (06) :1593-1598

[9] Brief report Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile [J].

Parker, Wendy T. ;

Ho, Musei ;

Scott, Hamish S. ;

Hughes, Timothy P. ;

Branford, Susan .

BLOOD, 2012, 119 (10) :2234-2238

[10] Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase [J].

Polakova, Katerina Machova ;

Kulvait, Vojtech ;

Benesova, Adela ;

Linhartova, Jana ;

Klamova, Hana ;

Jaruskova, Monika ;

de Benedittis, Caterina ;

Haferlach, Torsten ;

Baccarani, Michele ;

Martinelli, Giovanni ;

Stopka, Tomas ;

Ernst, Thomas ;

Hochhaus, Andreas ;

Kohlmann, Alexander ;

Soverini, Simona .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) :887-899

← 1 2 →